Search Results 1381-1390 of 19167 for Neutrophil

1. A Study to Evaluate Adjuvant Ado-Trastuzumab Emtansine (T-DM1) in HER2 Positive Breast Cancer - Mayo Clinic

   Absolute neutrophil count (ANC) ≥1500/mm3;; Platelet count ≥100,000/mm3;; Hemoglobin >9.0 g/dL;; Total bilirubin ≤1.5 x upper limit of normal (ULN). If ...

2. A Study to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors - Mayo Clinic

   Absolute Neutrophil count (ANC) ≥1.5 x10^9 /L (without granulocute coloty-stimulating support);; Absolute Lymphocyte count (ALC) ≥ 0.5 x 10^9 /L ...

3. A Study to Evaluate Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Older Patients With Untreated Chronic Lymphocytic Leukemia - Mayo Clinic

   Absolute Neutrophil Count (ANC) ≥ 1,000/mm^3 except if due to bone marrow involvement. Platelet Count (untransfused) ≥ 30,000/mm^3. Calc. Creatinine ...

4. Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors - Mayo Clinic

   Neutrophils ≥1,500 μL. Platelets ≥100,000 μL. Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤ 3 upper limit of normal (ULN). In cases ...

5. A Study to Test the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer - Mayo Clinic

   Absolute neutrophils ≥ 1,500/mcL. Platelets ≥ 100,000/mcL. Hemoglobin ≥ 9 g/dL. Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); ...

6. A Study Of Patients Treated For Chronic Granulomatous Disease Since 1995 - Mayo Clinic

   Participation eligibility · CGD Patients will be defined by both Defective Neutrophil NADPH Oxidase Function and by clinical history consistent with CGD ...

7. Phase 2b Study of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis - Mayo Clinic

   Neutrophil blood count < 1500/µL;; Prolongation of prothrombin time and partial thromboplastin time > 1.5 × ULN, or international normalized ratio > 2; or ...

8. A Study to Evaluate Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy - Mayo Clinic

   Absolute neutrophil count ≥ 1,500/mcL (obtained ≤ 28 days prior to protocol registration). Platelets ≥ 100,000/mcL (obtained ≤ 28 days prior to protocol ...

9. Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS) - Mayo Clinic

   Clinically-significant inadequate hematological, hepatic and renal function, defined as: Neutrophil count < 1.5 x 10^9/L and platelet count < 100 x 10^9/L ...

10. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of WSD0922-FU - Mayo Clinic

    Absolute neutrophil count > 1.5 x 109/L; Platelets > 100 x 109/L; INR < 1.5 x upper limit of normal (ULN)*; aPTT < 1.5 x ULN*. *Patients on a stable dose of ...